Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: A retrospective cost analysis

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Akazawa, Manabu ^a   Fukuoka, Katsushi ^b  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b Nihon Life Co Ltd   (Japan)

Author keywords

Antihypertensive drug; Drug costs; Economic benefit; Fixed dose combination; Social experiment; Switching

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; COMPARATIVE STUDY; COST; DRUG COMBINATION; DRUG SUBSTITUTION; ECONOMICS; FEMALE; HUMAN; HYPERTENSION; INSURANCE; JAPAN; MALE; MIDDLE AGED; PHARMACY; RETROSPECTIVE STUDY;

AGED; ANTIHYPERTENSIVE AGENTS; COSTS AND COST ANALYSIS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; JAPAN; MALE; MIDDLE AGED; PHARMACIES; RETROSPECTIVE STUDIES;

EID: 84875660752     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-124     Document Type: Article

References (35)

1. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee, Hypertension 2003 42 6 1206 1252 10.1161/01.HYP.0000107251.49515.c2 14656957 (Pubitemid 37553153)
2. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology, Eur Heart J 2007 28 12 1462 1536 17562668
3. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee, Hypertens Res 2009 32 1 3 107 19300436
4. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M, Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension Investigators, Blood Press 2008 17 1 7 17 10.1080/08037050801972857 18568687 (Pubitemid 351890487)
5. Current status of antihypertensive prescription and associated blood pressure control in Japan. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S, Hypertens Res 2006 29 3 143 151 10.1291/hypres.29.143 16755149
6. Hypertension management in diabetic patients: prescribing trends from 1999 to 2005 in three Japanese university hospitals. Kamijima Y, Ooba N, Yagame M, Samizo K, Shimodozono Y, Kageyama S, Horiguchi S, Nagai R, Kusunoki T, Kubota K, Pharmacoepidemiol Drug Saf 2008 17 9 904 911 10.1002/pds.1609 18461632
7. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Sakima A, Ohshiro K, Nakada S, Yamazato M, Kohagura K, Nakamoto M, Tana T, Ohya Y, Clin Exp Hypertens 2011 33 5 309 315 10.3109/10641963.2010. 549260 21649528
8. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate benazepril HCl versus comparable component-based therapy. Taylor AA, Shoheiber O, Congest Heart Fail 2003 9 324 332 10.1111/j.1527-5299.2003.03269.x 14688505
9. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Curr Med Res Opin 2008 24 9 2597 2607 10.1185/03007990802319364 18812017
10. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Neutel JM, Curr Med Res Opin 2008 24 8 2389 2401 10.1185/03007990802262457 18616863
11. Out-of-pocket and total costs of fixed dose combination antihypertensives and their components. Rabbani A, Alexander GC, Am J Hypertens 2008 21 509 513 10.1038/ajh.2008.31 18437141 (Pubitemid 351589682)
12. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Gupta AK, Arshad S, Poulter NR, Hypertension 2010 55 2 399 407 10.1161/HYPERTENSIONAHA.109.139816 20026768
13. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. Baser O, Andrews LM, Wang L, Xie L, J Med Econ 2011 14 5 576 583 10.3111/13696998.2011.596873 21728914
14. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S, J Clin Hypertens (Greenwich) 2011 13 12 898 909 10.1111/j.1751-7176.2011.00550.x
15. Clinical and economic outcomes associated with amlodipine/renin- angiotensin system blocker combinations. Ferrario CM, Panjabi S, Buzinec P, Swindle JP, Ther Adv Cardiovasc Dis 2013 Epub ahead of print
16. Reducing costs and improving hypertension management. Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT, Can J Clin Pharmacol 2009 16 1 151 e155 19193969
17. Comparison of amlodipine valsartan fixed-dose combination therapy and conventional therapy. Malesker MA, Hilleman DE, Manag Care 2010 19 36 42 21291131
18. Out-of-pocket costs to users: medicine options for hypertension. Arredondo A, Am J Hypertens 2008 21 492 10.1038/ajh.2008.150 18437138 (Pubitemid 351589670)
19. The Japanese generic drug market: opportunities and strategies for success http://thomsonreuters.com/content/science/pdf/ls/newport-japanese- generics.pdf
20. Pharmaceutical Pricing and Reimbursement in Japan. John Wiley & Sons Ltd, Handbook of Current and Emerging Drug Therapies, Volume 5-8 Hoboken NJ: Wiley 2007 205 237
21. Japan Pharmaceutical Manufacturers Association (JPMA), Health Insurance Programs and Drug Pricing in Japan (Chapter 6). Pharmaceutical Administration and Regulations in Japan (March 2012) http://www.jpma.or.jp/english/
22. Impact of prescription-term deregulation with revised medical service fees on drug therapy management. Kawazoe H, Iihara N, Doi C, Morita S, Yakugaku Zasshi 2005 125 12 959 969 10.1248/yakushi.125.959 16327241 (Pubitemid 41746153)
23. Pharmaceutical Research and Manufactures of America News Release February 25, 2010 http://www.phrma-jp.org/archives/newsroom/release/nr2010/100225-1300. php
24. Central Social Insurance Medical Council (Chiukyo) meeting October 27, 2010 http://www.mhlw.go.jp/stf/shingi/2r9852000000uygm-att/2r9852000000uymx.pdf
25. Ministry of Health, Labour and Welfare, Reimbursement of medical fees in 2012 http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou-iryou/iryouhoken/ iryouhoken15/index.html
26. Pooling cross sections across time, simple panel data method (Chapter 13). Wooldridge JM, Introductory Econometrics: A Modern Approach. 2nd edition Mason OH: South-Western 2003 426 460
27. Japanese Ethical Guidelines for Epidemiological Research (In Japanese). 2008 http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html
28. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI, Clin Ther 2008 30 8 1558 1563 10.1016/j.clinthera.2008.08.010 18803997
29. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. Patel BV, Remigio-Baker RA, Thiebaud P, Preblick R, Plauschinat C, BMC Fam Pract 2008 9 61 68 10.1186/1471-2296-9-61 18990240
30. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE, Curr Med Res Opin 2010 26 12 2877 2887 10.1185/03007995.2010.534129 21067459
31. A checklist for medication compliance and persistence studies using retrospective databases. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M, Value Health 2007 10 1 3 12 10.1111/j.1524-4733. 2006.00139.x 17261111 (Pubitemid 46161090)
32. Drug utilization reviews by community pharmacists in Japan: identification of potential safety concerns through the brown bag program. Akazawa M, Nomura K, Kusama M, Igarashi A, Value Health Regional Issues 2012 1 98 104
33. Japan Pharmaceutical Association, Annual report of JPA 2010-2011 http://www.nichiyaku.or.jp/e/data/annual-report2010e.pdf
34. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB, Value Health 2010 13 6 846 852 10.1111/j.1524-4733.2010.00730.x 20561344
35. Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach. Sun P, Chang J, Zhang J, Kahler KH, J Med Econ 2012 15 1 8 18 10.3111/13696998.2011.626097 22011107